Marek Roik

Prof. Marek Roik

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Irene M. LangIrene M. Lang
Irene M. Lang
AAArne K Andreassen
Arne K Andreassen
AAAsger Andersen
Asger Andersen
HBHelene Bouvaist
Helene Bouvaist
GCGerry Coghlan
Gerry Coghlan
PBPhilippe Brenot
Philippe Brenot
The current treatment algorithm for chronic thromboembolic pulmonary hypertension (CTEPH) as depicted in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines on the diagnosis and treatment of pulmonary hypertension (PH) includes a multimodal approach of combinations of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA) and medical therapies to target major vessel pulmonary vascular lesions, and microvasculopathy. Today, BPA of >1700 patients has been reported in the literature from centers in Asia, the US, and also Europe; many more patients have been treated outside literature reports. As BPA becomes part of routine care of patients with CTEPH, benchmarks for safe and effective care delivery become increasingly important. In light of this development, the ESC Working Group on Pulmonary Circulation and Right Ventricular Function has decided to publish a document that helps standardize BPA to meet the need of uniformity in patient selection, procedural planning, technical approach, materials and devices, treatment goals, complications including their management, and patient follow-up, thus complementing the guidelines. Delphi methodology was utilized for statements that were not evidence based. First, an anatomical nomenclature and a description of vascular lesions are provided. Second, treatment goals and definitions of complete BPA are outlined. Third, definitions of complications are presented which may be the basis for a standardized reporting in studies involving BPA. The document is intended to serve as a companion to the official ESC/ERS guidelines.

1 January 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
MRMarek Roik
Marek Roik
DWDominik Wretowski
Dominik Wretowski
AŁAndrzej Łabyk
Andrzej Łabyk
MKMaciej Kostrubiec
Maciej Kostrubiec
KIKatarzyna Irzyk
Katarzyna Irzyk
PPPiotr Pruszczyk
Piotr Pruszczyk

28 April 2023 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
Grzegorz KopecGrzegorz Kopec
Grzegorz Kopec
Aleksander AraszkiewiczAleksander Araszkiewicz
Aleksander Araszkiewicz
Marcin Kurzyna, MD, PhD, FESCMarcin Kurzyna, MD, PhD, FESC
Marcin Kurzyna, MD, PhD, FESC
Sylwia Sławek-SzmytSylwia Sławek-Szmyt
Sylwia Sławek-Szmyt
JSJakub Stępniewski
Jakub Stępniewski
PPPiotr Pruszczyk
Piotr Pruszczyk
Thanks to advances in interventional cardiology technologies, catheter-directed treatment has become recently a viable therapeutic option in the treatment of patients with acute pulmonary embolism at high risk of early mortality. Current transcatheter techniques allow for local fibrinolysis or embolectomy with minimal risk of complications. Therefore, these procedures can be considered in high-risk patients as an alternative to surgical pulmonary embolectomy when systemic thrombolysis is contraindicated or ineffective. They are also considered in patients with intermediate-high-risk pulmonary embolism who do not improve or deteriorate clinically despite anticoagulation. The purpose of this article is to present the role of transcatheter techniques in the treatment of patients with acute pulmonary embolism. We describe current knowledge and expert opinions in this field. Interventional treatment is described in the broader context of patient care organization and therapeutic modalities. We present the organization and responsibilities of pulmonary embolism response team, role of pre-procedural imaging, periprocedural anticoagulation, patient selection, timing of intervention, and intensive care support. Currently available catheter-directed therapies are discussed in detail including standardized protocols and definitions of procedural success and failure. This expert opinion has been developed in collaboration with experts from various Polish scientific societies, which highlights the role of teamwork in caring for patients with acute pulmonary embolism.

5 May 2017 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
PDF file
MRMarek Roik
Marek Roik
DWDominik Wretowski
Dominik Wretowski
AŁAndrzej Łabyk
Andrzej Łabyk
KIKatarzyna Irzyk
Katarzyna Irzyk
BLBarbara Lichodziejewska
Barbara Lichodziejewska
PPPiotr Pruszczyk
Piotr Pruszczyk

31 December 2008 in Acta Cardiologica
Verified
Journal Article
Closed access
MRMarek Roik
Marek Roik
MSM.H. Strarczewska
M.H. Strarczewska
ZHZenon Huczek
Zenon Huczek
JKJ. Kochanowski
J. Kochanowski
GOG. Opolski
G. Opolski
A number of medications such as beta-blockers,ACE-inhibitors, angiotensin receptor blockers and aldosterone antagonists, improve survival in patients with heart failure (HF) and reduced ejection fraction. No therapy has been proved to be beneficial for patients with heart failure and preserved ejection fraction (PLVEF). The aim of the study was to assess the effect of statin therapy on all-cause mortality and cardiovascular rehospitalization rate in patients with HF and PLVEF during one-year follow-up. We evaluated 146 patients with HF and PLVEF (ejection fraction > or = 45%). Patients were divided into the statin therapy group (n = 103, mean age 69 +/- 11 y, 52 men) and the group without statins (n = 43, mean age 66 +/- 16 y, 25 men).We analysed the effects of the statin treatment prescribed to patients at discharge. Patients were followed up for one year. The age, gender, NYHA functional class, prevalence of co-morbidities (renal dysfunction, COPD, diabetes mellitus) did not differ between the groups (P = NS). Patients receiving statin therapy more frequently had an ischaemic aetiology of HF (79% vs. 39.5%; P < 0.001) and hypertension (76% vs. 58%; P < 0.05). No differences in ejection fraction were observed neither by echocardiography (58% vs. 55%; P = NS) nor by basic laboratory data. Patients who received statins were often additionally treated with beta-blockers (91% vs. 70%; P < 0.005), aspirin (77 vs. 44%; P < 0.01), thienopyridines (22% vs. 5%; P < 0.01) and less frequently with oral anticoagulants (5% vs. 23%; P < 0.005). In the group receiving statins a significantly lower mortality (4% vs. 21%; P < 0.001) and rehospitalization rate (43% vs. 69%; P < 0.05) was documented. After adjustment for all univariate predictors of the occurrence of study primary end-points, statin therapy was shown to be associated with significant and independent reduction in all-cause mortality (HR = 0.24 [95%CI:0.07 - 0.90] P < 0.05) and cardiovascular rehospitalization rate (HR = 0.55 [95%CI: 0.33 - 0.92] P< 0.05). After propensity matching statin therapy remained an independent factor reducing one-year mortality rate (HR = 0. 11 [95%CI: 0.01 - 0.99] P < 0.05]. This study showed that statin therapy may have beneficial effects on mortality and rehospitalization rates among patients with HF and PLVEF. It also suggests a potential role for statins as a new therapeutic option in patients with HF and PLVEF, but these observations need to be confirmed in large randomized trials.

21 October 2005 in European Heart Journal
Verified
Journal Article
Open access
PDF file
GHGrzegorz J. Horszczaruk
Grzegorz J. Horszczaruk
MRMarek Roik
Marek Roik
JKJanusz Kochman
Janusz Kochman
LBLeopold Bakoń
Leopold Bakoń
PSPrzemysław Stolarz
Przemysław Stolarz
GOGrzegorz Opolski
Grzegorz Opolski
A 66-year-old woman was admitted after an episode of faint with concomitant severe chest pain lasting ∼2 h. Typical retrosternal localization of the pain with ST-elevation (Pardee wave) in leads II, III, and aVF, and ST-depression in I, V1–V3 allowed to diagnose acute infero-posterior myocardial infarction. ECG also revealed temporal second-degree atrioventricular block (Mobitz II). Blood pressure was 140/70 mmHg and HR was 55 b.p.m. No distinct murmur was heard on cardiac auscultation. In coronary angiography, left coronary artery had no significant stenoses. After placing the catheter in the ostium of RCA, no severe stenosis was seen and the flow was normal (TIMI 3, MBG 3). Just after selective cannulation of the RCA, chest pain diminished and ST-elevation recovered. Of note, during the peak of dye injection, the lumen was distended and collapsed at the end of the injection in the proximal segment of the artery. However, in coronary angiography, the lumen of RCA seemed not to be narrowed significantly (Panel A). To thoroughly assess the vessel, intracoronary ultrasound (ICUS) was performed. No evident atheromatous plaque was present in proximal part of RCA. During manual pullback, a hypoechoic mass adjacent to proximal segment of the artery was clearly seen (Panel B). The lumen in proximal segment and in ostium of RCA was impressed and narrowed by that mass (Panel C). Such hypoechoic mass parallel to the artery is not normally seen at this site. It was suspected that false channel existed and was propagated from the aorta to the proximal part of RCA. Therefore, dissecting aneurysm of the aorta was strongly suspected. It is important that almost immediately after withdrawal of a catheter from the ostium of RCA, the signs of acute myocardial ischaemia (i.e. severe chest pain and ST-elevation) relapsed. We thought that the catheter kept the lumen of RCA patent enabling restoration flow through the artery. Computed tomography (CT) fully confirmed our diagnosis of dissecting aneurysm—revealing long dissection extending from aortic valve up to the renal arteries with false lumen being partly thrombosed. CT showed patent left coronary artery and lack of patency of the RCA (Panel D).